Promoters for Glaucoma Gene Therapy
About the Research Project
Program
Award Type
Standard
Award Amount
$49,986
Active Dates
April 01, 1999 - March 31, 2001
Grant ID
G1999005
Summary
Gene therapy may prove to be an ideal form of treatment for diseases with genetic causes because a normal version of a gene could be introduced into cells to restore functions that have been disrupted due to the genetic mutation. If gene therapy is to be used one day for treating forms of glaucoma, two requirements must be met. First, one needs an efficient means, or vector, for placing genes in eye tissues. Second, genetic elements called promoters are required that will allow the therapeutic gene to be specifically turned on in the appropriate cell type (e.g. TM cells). Dr. Brandt has already attained the first goal and is now focused on identifying TM cell-specific promoters.
Related Grants
National Glaucoma Research
Pressure-Induced Axon Damage and Its Link to Glaucoma-Related Vision Loss
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Bingrui Wang, PhD
Current Organization
University of Pittsburgh
Pressure-Induced Axon Damage and Its Link to Glaucoma-Related Vision Loss
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Bingrui Wang, PhD
Current Organization
University of Pittsburgh
National Glaucoma Research
Why Certain Retina Ganglion Cells Stay Strong in Glaucoma
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Mengya Zhao, PhD
Current Organization
University of California, San Francisco
Why Certain Retina Ganglion Cells Stay Strong in Glaucoma
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Mengya Zhao, PhD
Current Organization
University of California, San Francisco
National Glaucoma Research
How the Microenvironment Affects Schlemm’s Canal Cell Behavior
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Samuel Herberg, PhD
Current Organization
SUNY Upstate Medical University
How the Microenvironment Affects Schlemm’s Canal Cell Behavior
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Samuel Herberg, PhD
Current Organization
SUNY Upstate Medical University